Clinical Dialogues in Pain: Management of Opioid-Induced Constipation
Release Date: May 14, 2013
Expiration Date: May 14, 2014
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This two-part educational activity focuses on the management of opioid-induced constipation (OIC). In module one, Dr. Gudin discusses the assessment and current and emerging treatment therapies as well as safety, efficacy, and alternative strategies for treating OIC. In module two, Dr. Herndon will present a case and discuss the pathophysiology of OIC. Each module will summarize key points as clinical pearls that support application of the knowledge presented in the clinical setting.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in pain management.
Upon completion of this educational activity, participants should be able to:
- Identify assessment techniques available to determine patients at risk of OIC
- Develop individualized strategies which include maintaining pain relief while minimizing or treating OIC
- Describe current and emerging strategies for preventing and/or treating OIC in patients with chronic pain
Clinical Dialogues in Pain: Management of Opioid-Induced Constipation – Jeffrey A. Gudin, MD
Clinical Dialogues in Pain: Management of Opioid-Induced Constipation ‒ A Case Presentation – Chris Herndon, PharmD, BCPS, CPE
Instructions for Participation and Credit
This activity is eligible for credit through May 14, 2014. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Jeffrey A. Gudin, MD
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.
An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.
Chris Herndon, PharmD, BCPS, CPE
Southern Illinois University Edwardsville
Dr. Chris Herndon received his doctor of pharmacy degree from the St. Louis College of Pharmacy. He then completed a geriatric pharmacotherapy specialty residency at the University of New Mexico Health Sciences Center. He is currently an associate professor at Southern Illinois University Edwardsville.
Dr. Herndon is a certified pain educator, American Society of Pain Educators, and a pharmacotherapy specialist, Board of Pharmaceutical Specialties, and is also a member of the International Association for the Study of Pain, American Society of Pain Educators, American Pain Society, and a fellow, American Society of Health-System Pharmacists. He holds editorial board positions at Journal of Pain and Palliative Care Pharmacotherapy and Journal of Opioid Management, and is an ad hoc reviewer for several professional publications. He has lectured and published numerous manuscripts, book chapters and abstracts and his research interests focus on pain and palliative care.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-347-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-347-310
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Alere, Covidien, Endo Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Purdue Pharma L.P., Salix Pharmaceuticals, Inc., and Teva Pharmaceuticals.
Dr. Christopher Herndon has received honoraria as a consultant from Endo Pharmaceuticals Inc., Incline Therapeutics, Inc., and Premier Research.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Bronwyn Boyes, PharmD, director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Gudin has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Herndon has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Gudin and Dr. Herndon have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.